Antitoxin strategy may help target other pathogens

June 18, 2012
This is an illustration of heterodimer chain attaching to Botulinum molecule at various binding sites. Credit: Illustration courtesy Beth Mellor/TUFTS

Researchers have unveiled a novel strategy for neutralizing unwanted molecules and clearing them from the body.

The strategy employs chains of binding agents, like "beads on a string", which two sites on one or more pathogenic molecules to neutralize their activity and promote their clearance by the body's immune system. The low-cost, easy-to-replicate tool has demonstrated applications against several different toxins, from those found in to those used in , and may also prove effective in targeting other types of pathogens.

The research team, based at Tufts University's Cummings School of Veterinary Medicine, demonstrated the method's efficacy in preventing the symptoms of botulism, a rare but caused by neurotoxin (BoNT), considered one of the most dangerous bioterror threat agents. The findings were presented earlier this year in .

"Currently, antitoxins are difficult to produce and have a short , making them very expensive. This new approach provides a low-cost way to develop highly effective antitoxins," said senior author Charles B. Shoemaker, PhD, professor of at Tufts University's Cummings School of Veterinary Medicine.

"This method has the potential to target a number of pathogens – not only toxins such as BoNT, but viruses or inflammatory cytokines. It is an important platform through which to address other significant diseases," says co-author Saul Tzipori, BVSc., DSc, PhD, professor of biomedical sciences and director of the Division of Infectious Diseases at the Cummings School.

Shoemaker and team had earlier found that pools of small 'tagged' binding agents were highly effective in targeting toxins, neutralizing their function, and flagging them for removal via the body's immune system in the presence of an anti-tag monoclonal antibody.

In the newly published in vivo study, the researchers have advanced this approach by linking two BoNT-binding agents together and including two copies of the tag. The binding agents are small, stable proteins derived genetically from unusual antibodies produced by toxin-immune alpacas. The resulting molecule, called a 'double-tagged heterodimer,' binds to two separate sites on the . Binding of this single heterodimeric agent much more effectively neutralizes the toxin than the unlinked monomer binding agents used in the prior research. In addition, attaching two tags to each of the two linked agents leads to toxin decoration by up to four anti-tag monoclonal antibodies, which promotes rapid toxin clearance from the blood, the researchers found (see figure).

The double-tagged heterodimer antitoxin agent strategy was shown to be efficacious against two types of BoNT in the PLoS ONE report. The antitoxin agents were administered at the time of exposure, or shortly after. Treated mice did not show any symptoms of – including the lethal paralysis which characterizes the disease, even when exposed to high toxin doses. Thus, the benefits of complex antitoxins were equaled or bettered by administration of two easy-to-produce agents; a heterodimer binding agent and an anti-tag monoclonal antibody.

According to Shoemaker, a major advantage of this approach is that, unlike treatments that only neutralize toxins, this treatment both neutralizes toxins and ensures their rapid clearance from the body. "Agents that only neutralize their pathogenic target will eventually dissociate which will allow the pathogen to continue doing damage if it is not eliminated," he said.

The group has now successfully taken the research further by building longer strings of binding agents that target multiple toxins with a single molecule—for example, the two types of Shiga toxins that are produced by some E. coli found in contaminated foods or the two toxins produced by hospital-acquired C. difficile infections.

Explore further: Newly discovered cell mechanism uses amplified nitric oxide to fight C. diff

More information: Mukherjee J, Tremblay JM, Leysath CE, Ofori K, Baldwin K, et al. "A Novel Strategy for Development of Recombinant Antitoxin Therapeutics Tested in a Mouse Botulism Model." PLoS ONE 7(1): e29941. Published online January 6, 2012, doi: 10.1371/journal.pone.0029941

Related Stories

Newly discovered cell mechanism uses amplified nitric oxide to fight C. diff

August 21, 2011
Groundbreaking research encompassing Case Western Reserve University School of Medicine and University Hospitals Case Medical Center, has uncovered a natural defense mechanism that is capable of inactivating the toxin that ...

Recommended for you

Are stem cells the link between bacteria and cancer?

August 17, 2017
Gastric carcinoma is one of the most common causes of cancer-related deaths, primarily because most patients present at an advanced stage of the disease. The main cause of this cancer is the bacterium Helicobacter pylori, ...

Two-step process leads to cell immortalization and cancer

August 17, 2017
A mutation that helps make cells immortal is critical to the development of a tumor, but new research at the University of California, Berkeley suggests that becoming immortal is a more complicated process than originally ...

New Pathology Atlas maps genes in cancer to accelerate progress in personalized medicine

August 17, 2017
A new Pathology Atlas is launched today with an analysis of all human genes in all major cancers showing the consequence of their corresponding protein levels for overall patient survival. The difference in expression patterns ...

Female mouse embryos actively remove male reproductive systems

August 17, 2017
A protein called COUP-TFII determines whether a mouse embryo develops a male reproductive tract, according to researchers at the National Institutes of Health and their colleagues at Baylor College of Medicine, Houston. The ...

New technique overcomes genetic cause of infertility

August 17, 2017
Scientists have created healthy offspring from genetically infertile male mice, offering a potential new approach to tackling a common genetic cause of human infertility.

Inhibiting a protein found to reduce progression of Alzheimer's and ALS in mice

August 17, 2017
(Medical Xpress)—A team of researchers with Genetech Inc. and universities in Hamburg and San Francisco has found that inhibiting the creation of a protein leads to a reduction in the progression of Alzheimer's disease ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.